Galmed Pharmaceuticals
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 8
- Market Cap
- $1.8M
- Website
- http://galmedpharma.com
- Introduction
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
Clinical Trials
12
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A study to compare two different aramchol formulations in healthy volunteers.
- Conditions
- Nonalcoholic fatty liver diseaseNonalcoholic steatohepatitisPrimary sclerosing cholangitis
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- CCDRD Cooperative Clinical Drug Research and Development AG, Galmed Research And Development Ltd.
- Target Recruit Count
- 16
- Registration Number
- 2023-507445-28-00
- Locations
- 🇧🇬
Bed space for short term stay at Diagnostic & Consultative Centre 'Ascendent' Ltd., Sofia, Bulgaria
An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Galmed Pharmaceuticals Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT05874336
- Locations
- 🇬🇧
Quotient Sciences, Mere Way, Ruddington Fields, Ruddington, Nottingham, NG11 6JS, UK., Nottingham, United Kingdom
A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Galmed Pharmaceuticals Ltd
- Target Recruit Count
- 55
- Registration Number
- NCT05857215
- Locations
- 🇬🇧
Quotient Sciences, Mere Way, Ruddington, Nottingham, NG11 6JS, UK, Nottingham, United Kingdom
Comparison of Aramchol Concentrations With Once or Twice Daily Dosing
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Galmed Pharmaceuticals Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT03774173
- Locations
- 🇬🇧
Hammersmith Medicines Research (HMR), London, United Kingdom
Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- Galmed Pharmaceuticals Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT03760848
- Locations
- 🇬🇧
Hammersmith Medicines Research (HMR), London, United Kingdom
- Prev
- 1
- 2
- Next
News
Aramchol Shows Significant Anti-Fibrotic Effects in MASH Patients, Phase 3 Trial Results Published in Hepatology
• Aramchol 300mg BID demonstrates a significant anti-fibrotic effect in patients with metabolic dysfunction-associated steatohepatitis (MASH), as confirmed by multiple objective measurements. • The Phase 3 trial (ARCON) utilized NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis to validate the data. • Digital pathology images analysis (DIA) provides continuous histological fibrosis scores, quantifying anti-fibrotic effects with greater sensitivity than conventional pathology. • Galmed believes Aramchol's unique mechanism of action positions it as a potent anti-fibrotic compound for combination therapy in MASH treatment.